Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 06-08-2022 | Carbapenem Antibiotic | Original Article

Implementation of Chromatic Super CAZ/AVI^® medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral

Authors: Gabriele Bianco, Matteo Boattini, Sara Comini, Alessio Leone, Alessandro Bondi, Teresa Zaccaria, Rossana Cavallo, Cristina Costa

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2022

Abstract

Acquired resistance towards ceftazidime-avibactam (CAZ-AVI) is increasingly reported. Several mechanisms can be involved, but mutations in the Ω-loop region of β-lactamases are the most described. Herein, we assessed the implementation of Chromatic Super CAZ/AVI^® medium in rectal swab surveillance cultures in a geographic area with endemic distribution of KPC-producing Klebsiella pneumoniae. Routine rectal swabs collected from the intensive care unit (ICU) and non-ICU patients were screened for carbapenemase-producing Enterobacterales (CPE), carbapenem-resistant Gram-negative organisms (CR-GN) and CAZ-AVI-resistant organisms by Chromatic CRE and Super CAZ/AVI^® media. Among the 1839 patients screened, 146 (7.9%) were found to be colonized by one or more CPE and/or CR-GN isolates during hospitalization. Overall, among colonized patients the most common bacteria encountered were KPC-producing Enterobacterales (n = 60; 41.1%), carbapenem-resistant Pseudomonas aeruginosa (n = 41; 28.1%) and carbapenem-resistant A. baumannii (n = 34; 23.3%). Among patients colonized by KPC-producing Enterobacterales, thirty-five (58.3%) had CAZ-AVI-resistant strains. A 30.5% rate of faecal carriage of CAZ-AVI-resistant KPC-producing K. pneumoniae, substantially higher than that of susceptible isolates (2.8%), was observed in the COVID-19 ICU. Prevalence of faecal carriage of metallo-β-lactamase-producing organisms was low (0.5% and 0.2% for Enterobacterales and P. aeruginosa, respectively). Chromatic Super CAZ/AVI^® medium showed 100% sensitivity in detecting CPE or CR-GN isolates resistant to CAZ-AVI regardless of both MIC values and carbapenemase content. Specificity was 86.8%. The Chromatic Super CAZ/AVI^® medium might be implemented in rectal swab surveillance cultures for identification of patients carrying CAZ-AVI-resistant organisms to contain the spread of these difficult-to-treat pathogens.

Available only for authorised users

Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L (2020) New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 34:e00115-e120. https://doi.org/10.1128/CMR.00115-20.Erratum.In:ClinMicrobiolRev.2021;34CrossRefPubMedPubMedCentral

Allergan. AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use. 2020. https://www.allergan.com/assets/pdf/avycaz_pi. Accessed 8 February 2022

Pfizer. Summary of Product Characteristics: Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion. 2021. https://www.ema.europa.eu/documents/product-information/zavicefta-epar-product-information_en.pdf. Accessed 8 February 2022

Wang Y, Wang J, Wang R, Cai Y (2020) Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist 22:18–27. https://doi.org/10.1016/j.jgar.2019.12.009CrossRefPubMed

Di Bella S, Giacobbe DR, Maraolo AE, Viaggi V, Luzzati R, Bassetti M et al (2021) Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist 25:268–281. https://doi.org/10.1016/j.jgar.2021.04.001CrossRefPubMed

Bianco G, Boattini M, Iannaccone M, Bondi A, Ghibaudo D, Zanotto E et al (2021) Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: a 2-year experience. J Glob Antimicrob Resist 24:411–414. https://doi.org/10.1016/j.jgar.2021.02.008CrossRefPubMed

Bianco G, Boattini M, Bondi A, Comini S, Zaccaria T, Cavallo R et al (2022) Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures. J Hosp Infect 122:217–219. https://doi.org/10.1016/j.jhin.2022.02.001CrossRefPubMedPubMedCentral

Sadek M, Poirel L, Tinguely C, Nordmann P (2020) A selective culture medium for screening ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa. J Clin Microbiol 58:e00965-e1020. https://doi.org/10.1128/JCM.00965-20.Erratum.In:JClinMicrobiol2020;58CrossRefPubMedPubMedCentral

Sadek M, Poirel L, Dominguez Pino M, D’Emidio F, Pomponio S, Nordmann P (2021) Evaluation of SuperCAZ/AVI® Medium for screening ceftazidime-avibactam resistant Gram-negative isolates. Diagn Microbiol Infect Dis 101:115475. https://doi.org/10.1016/j.diagmicrobio.2021.115475CrossRefPubMed

10.

Wilson AP, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA et al (2016) Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. J Hosp Infect 92(Suppl 1):S1-44. https://doi.org/10.1016/j.jhin.2015.08.007CrossRefPubMed

11.

Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U et al (2014) ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20(Suppl 1):1–55. https://doi.org/10.1111/1469-0691.12427CrossRefPubMed

12.

Tischendorf J, de Avila RA, Safdar N (2016) Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect Control 44:539–543. https://doi.org/10.1016/j.ajic.2015.12.005CrossRefPubMedPubMedCentral

13.

Bianco G, Boattini M, Iannaccone M, Pastrone L, Bondi A, Peradotto M et al (2021) Integrating rapid diagnostics in Gram-negative bloodstream infections of patients colonized by carbapenemase-producing Enterobacterales. J Hosp Infect 110:84–88. https://doi.org/10.1016/j.jhin.2021.01.015CrossRefPubMed

14.

Cano A, Gutiérrez-Gutiérrez B, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Causse M et al (2018) Risks of infection and mortality among patients colonized with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: validation of scores and proposal for management. Clin Infect Dis 66:1204–10. https://doi.org/10.1093/cid/cix991CrossRefPubMed

15.

Poirel L, Nordmann P. 2006 Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect:826–36. https://doi.org/10.1111/j.1469-0691.2006.01456.x.

16.

Comini S, Bianco G, Boattini M, Iannaccone M, Casale R, Banche G et al (2021) Evaluation of the Amplex eazyplex SuperBug Acineto test for direct detection of multi-drug-resistant Acinetobacter baumannii bloodstream infections in high endemicity settings. J Hosp Infect 117:179–181. https://doi.org/10.1016/j.jhin.2021.09.015CrossRefPubMed

17.

Stone GG, Seifert H, Nord CE (2020) In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015–2017. Int J Antimicrob Agents 56:106045. https://doi.org/10.1016/j.ijantimicag.2020.106045CrossRefPubMed

18.

Kiratisin P, Kazmierczak K, Stone GG (2021) In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. J Glob Antimicrob Resist 27:132–141. https://doi.org/10.1016/j.jgar.2021.08.010CrossRefPubMed

19.

European Centre for Disease Prevention and Control. Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae – 12 June 2018. Stockholm: ECDC; 2018. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-emergence-resistance-ceftazidime-avibactam-carbapenem. Accessed 10 March 2022

20.

Gaibani P, Lombardo D, Foschi C, Re MC, Ambretti S (2020) Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance. J Antimicrob Chemother 75:2010–2013. https://doi.org/10.1093/jac/dkaa079CrossRefPubMed

21.

Antonelli A, Giani T, Di Pilato V, Riccobono E, Perriello G, Mencacci A et al (2019) KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother 74:2464–2466. https://doi.org/10.1093/jac/dkz156CrossRefPubMed

Title: Implementation of Chromatic Super CAZ/AVI® medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral
Authors: Gabriele Bianco
Matteo Boattini
Sara Comini
Alessio Leone
Alessandro Bondi
Teresa Zaccaria
Rossana Cavallo
Cristina Costa
Publication date: 06-08-2022
Publisher: Springer Berlin Heidelberg
Keywords: Carbapenem Antibiotic
Ceftazidime
Pseudomonas Aeruginosa
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-022-04480-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Implementation of Chromatic Super CAZ/AVI^® medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2022

Genome-wide association study of SARS-CoV-2 infection in Chinese population

A systematic review and meta-analysis on the accuracy of rapid immunochromatographic tests for dengue diagnosis

Impact of therapeutic drug monitoring of antibiotics in the management of infective endocarditis

Treatment duration for central line-associated infection caused by Enterococcus spp.: a retrospective evaluation of a multicenter cohort

Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page